semaglutide and chronic kidney disease Effects of on in Patients with Type 2 Diabetes | NEJM Semaglutide in chronic kidney disease
Description
To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383)
doi:10.1007/s00125-017-4350-z 63
This compound should be treated with standard laboratory peptide handling protocols throughout all research procedures
2 Chronic kidney disease poses a significant risk of kidney failure, cardiovascular events and death, 3 highlighting the critical need for research into its prevention and treatment
All compounded medications undergo rigorous testing for sterility and endotoxins
Moreover, CICR requires continual activation of VDCCs by Ca 2+ within intracellular microdomains, but not by robust Ca 2+ influx from extracellular spaces [8,15,17,24]
